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Bisphosphonates (BPs) are a class of drugs widely used in the treatment of several metabolic 
bone disorders associated with increased bone resorption, including osteoporosis, Paget’s 
disease and metastic bone disease [1-3]. Although BPs can directly inhibit the cellular activity 
of osteoclasts, their ability to adsorb to bone mineral is also an important factor in determining 
their potency and duration of action [4]. In this study, we performed a molecular modelling 
analysis, by molecular mechanics [5], of the molecular structures of hydroxy(1H-indazol-3-
yl)methylene-diphosphonic acid (BP1; Figure 1a) and hydroxy(1-methyl-1H-indazol-3-yl)-
methylenediphosphonic acid (BP2; Figure 1b) and examined their interactions with 
hydroxyapatite by energy-minimising 50 different orientations for judiciously selected low 
energy conformers of each ligand at 10 Å from the mineral surface. Their interaction energy 
suggests that BP2 interacts stronger with hydroxyapatite than BP1. These results are in 
agreement with in vitro and in vivo studies of the 153Sm-BPs complexes. Complex 153Sm-BP2 
showed, in vitro, higher HA binding than complex 153Sm-BP1. In vivo studies showed different 
farmacokinetics parameters with complex 153Sm-BP2 presenting initial higher levels of bone 
uptake than complex 153Sm-BP1, which concentration is increasing during the 24 h period 
studied [6]. 
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Figure 1 – a) hydroxy(1H-indazol-3-yl)methylenediphosphonic acid – BP1; 
                                b) hydroxy(1-methyl-1H-indazol-3-yl)methylenediphosphonic acid– BP2. 
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